Add like
Add dislike
Add to saved papers

Omitting lymph node dissection for small ground glass opacity-dominant tumors.

BACKGROUND: The study purpose was to determine the optimal extent of lymph node dissection required in patients with small (≤ 3 cm) radiologically ground-glass opacity-dominant, peripheral, non-small cell lung cancer tumors.

METHODS: We analyzed the clinicopathological findings/surgical outcomes of 988 patients with radiological, ground glass opacity-dominant non-small cell lung cancer without lymph node involvement who underwent complete resection of the primary tumor between 2010 and 2020. Patients were followed for 54.5 months (median). Kaplan-Meier curves and log-rank test were used in statistical analyses of the prognosis.

RESULTS: Median age, whole tumor size, solid tumor size, and maximum standardized uptake value were 68 years, 1.7 cm, 0.4 cm, and 0.9, respectively. Sixty percent of the cohort were females (n = 590). Wedge resection, segmentectomy, and lobectomy were performed in 206, 372, and 410 patients, respectively. A total of 982 of 988 (99%) tumors were adenocarcinoma. One patient had hilar lymph node involvement; however, no mediastinal lymph node metastasis or hilar or mediastinal lymph node recurrence was detected. Five-year overall survival rate was 96.5% (95% confidence interval (CI): 94.8 - 97.7%). Excellent survival outcomes were achieved regardless of procedure (wedge resection, 94.7% [95% CI: 89.1 - 97.5%]; segmentectomy, 96.9% [95% CI: 93.7 - 98.5%]; lobectomy, 97.1% [95% CI: 94.4 - 98.5%]).

CONCLUSIONS: Omitting lymph node dissection may be acceptable with curative intent for small tumors with radiological ground glass opacity dominance. Appropriate surgical procedures such as wedge resection, segmentectomy, or lobectomy can provide satisfactory outcomes in patients with indolent tumors if surgical margins are secured.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app